Comparative Pharmacology
Head-to-head clinical analysis: BETHKIS versus STREPTOMYCIN SULFATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BETHKIS versus STREPTOMYCIN SULFATE.
BETHKIS vs STREPTOMYCIN SULFATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Tobramycin, an aminoglycoside antibiotic, binds to the 30S ribosomal subunit, causing misreading of mRNA and inhibiting protein synthesis, leading to bacterial cell death.
Aminoglycoside antibiotic that irreversibly binds to the 30S ribosomal subunit, inhibiting protein synthesis by causing misreading of mRNA and preventing initiation complex formation.
4 IU/kg (1 mg/kg) intramuscularly or subcutaneously once weekly for 4 weeks, then a maintenance dose of 2 IU/kg (0.5 mg/kg) once weekly.
Intramuscular: 15 mg/kg/day (max 1 g/day) divided every 12 hours; intraperitoneal: 1 g/dialysis cycle; intrathecal: 1 mg/kg/day.
None Documented
None Documented
Terminal elimination half-life 2-3 hours in patients with normal renal function; prolonged to 20-40 hours in severe renal impairment (CrCl <30 mL/min).
Terminal elimination half-life is 2-3 hours in patients with normal renal function. In anuria or severe renal impairment, half-life may extend to 50-100 hours. Neonates have a prolonged half-life of 5-10 hours due to immature renal function.
Primarily renal excretion of unchanged drug via glomerular filtration; ~90% of absorbed dose excreted in urine within 24 hours; biliary/fecal elimination <5%.
Primarily renal excretion via glomerular filtration; 80-98% of the dose is excreted unchanged in urine within 24 hours. Minor biliary excretion (less than 1%). Fecal excretion is negligible.
Category C
Category D/X
Aminoglycoside Antibiotic
Aminoglycoside Antibiotic